Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals PLC has successfully closed a $5.0 million funding round through a registered direct offering and a concurrent private placement, anticipating the use of the proceeds to fund development programs, including a Phase 3 clinical trial for eRapa in Familial Adenomatous Polyposis. The offering comprised over 5 million American Depositary Shares and pre-funded warrants, along with Series J and K warrants, with Ladenburg Thalmann & Co. Inc. serving as the sole placement agent. The funds are also slated for a $17 million grant match from CPRIT and to support general corporate purposes.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
